IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CRISCITIELLO, CARMEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.415
AS - Asia 9.625
NA - Nord America 8.524
SA - Sud America 916
AF - Africa 219
OC - Oceania 96
Continente sconosciuto - Info sul continente non disponibili 10
Totale 30.805
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.118
DE - Germania 4.024
CN - Cina 3.378
SG - Singapore 2.676
GB - Regno Unito 2.071
IT - Italia 1.961
HK - Hong Kong 925
BR - Brasile 709
VN - Vietnam 693
SE - Svezia 678
RU - Federazione Russa 639
FR - Francia 527
IN - India 418
BD - Bangladesh 390
NL - Olanda 346
JP - Giappone 284
CA - Canada 256
FI - Finlandia 236
IE - Irlanda 212
ES - Italia 171
ID - Indonesia 164
TR - Turchia 149
KR - Corea 135
AU - Australia 83
MX - Messico 83
AT - Austria 81
CH - Svizzera 77
TW - Taiwan 75
AR - Argentina 74
CI - Costa d'Avorio 64
PL - Polonia 53
PH - Filippine 43
BE - Belgio 42
DK - Danimarca 41
IQ - Iraq 38
CO - Colombia 35
RO - Romania 35
TH - Thailandia 34
ZA - Sudafrica 34
EG - Egitto 32
EC - Ecuador 31
UA - Ucraina 31
NO - Norvegia 29
GR - Grecia 28
IR - Iran 27
SA - Arabia Saudita 27
MY - Malesia 22
PK - Pakistan 22
CL - Cile 19
KE - Kenya 19
PT - Portogallo 19
VE - Venezuela 19
JO - Giordania 18
MA - Marocco 18
LT - Lituania 17
AE - Emirati Arabi Uniti 16
CR - Costa Rica 14
CZ - Repubblica Ceca 14
UZ - Uzbekistan 14
NZ - Nuova Zelanda 12
DZ - Algeria 11
JM - Giamaica 11
ET - Etiopia 10
PE - Perù 10
TN - Tunisia 10
BY - Bielorussia 9
IL - Israele 9
SK - Slovacchia (Repubblica Slovacca) 9
TT - Trinidad e Tobago 9
AM - Armenia 8
HU - Ungheria 8
LB - Libano 8
PS - Palestinian Territory 8
UY - Uruguay 8
AL - Albania 7
HN - Honduras 7
LU - Lussemburgo 7
SI - Slovenia 7
AP - ???statistics.table.value.countryCode.AP??? 6
CY - Cipro 6
GE - Georgia 6
RS - Serbia 6
SC - Seychelles 6
BG - Bulgaria 5
EU - Europa 5
HR - Croazia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
NG - Nigeria 5
PA - Panama 5
PY - Paraguay 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
LV - Lettonia 4
MD - Moldavia 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BO - Bolivia 3
EE - Estonia 3
Totale 30.758
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 3.541
Southend 1.823
Singapore 1.315
Ashburn 1.052
Hong Kong 781
Dallas 665
Milan 631
San Jose 595
Hefei 439
Beijing 433
Chandler 339
Council Bluffs 325
Fairfield 313
Houston 307
Los Angeles 255
New York 211
Santa Clara 208
Dublin 207
Guangzhou 198
Ho Chi Minh City 197
Wilmington 193
Princeton 190
Lauterbourg 179
Bengaluru 170
Helsinki 170
Shanghai 166
Hanoi 164
Moscow 147
Boardman 144
Nanjing 144
Seattle 135
Rome 127
Woodbridge 127
Redwood City 122
Buffalo 121
Cambridge 120
Jakarta 108
Tokyo 102
São Paulo 95
Seoul 90
Toronto 83
Istanbul 82
Ann Arbor 78
Des Moines 70
Naples 70
Dearborn 65
Abidjan 64
Munich 62
Cangzhou 61
Columbus 60
Hangzhou 59
Shenyang 59
Phoenix 58
The Dalles 56
Jinan 51
Vienna 51
Atlanta 49
Amsterdam 45
Tianjin 45
Turin 45
San Diego 43
Changsha 42
London 42
Da Nang 41
Hyderabad 40
Nuremberg 40
Zhengzhou 36
Düsseldorf 35
Washington 34
Wuhan 34
Lappeenranta 33
Montreal 33
Florence 32
Shenzhen 32
Chicago 31
Taipei 31
Fuzhou 30
Boston 29
Paris 29
Madrid 27
Rio de Janeiro 27
Berlin 26
Sunnyvale 26
Hanover 25
Bologna 24
Hebei 24
Mexico City 24
Grafing 23
Orem 22
Silver Spring 22
Bari 21
Haiphong 21
McAllen 21
Sydney 21
Barcelona 20
Chennai 20
Philadelphia 20
Rho 20
Dong Ket 19
Pune 19
Totale 19.001
Salva come PNG Salva come JPEG
Nome #
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1.461
Entinostat for the treatment of breast cancer 895
Global cancer control: responding to the growing burden, rising costs and inequalities in access 847
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 838
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 760
Managing side effects of immune checkpoint inhibitors in breast cancer 375
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 324
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 322
Expression of tumor-associated antigens in breast cancer subtypes 317
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs 312
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 305
Antibody–drug conjugates in solid tumors: a look into novel targets 290
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 287
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 278
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 263
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology 260
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 251
Metaplastic breast cancer: an all-round multidisciplinary consensus 249
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 248
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 244
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 243
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 241
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study 234
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 224
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 224
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 224
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 218
Evolution of low HER2 expression between early and advanced-stage breast cancer 213
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 212
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 212
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study 209
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 204
Future potential targets of antibody-drug conjugates in breast cancer 202
Tumour dormancy and clinical implications in breast cancer 201
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 201
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 200
Impact of autoimmune diseases on outcome of patients with early breast cancer 199
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 198
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 196
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 195
Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer 194
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 194
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials 193
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 193
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment 192
Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer 192
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 191
Highlights from the 13th St Gallen International Breast Cancer Conference 2013 : access to innovation for patients with breast cancer: How to speed it up? 191
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 191
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 190
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 185
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 184
Immune approaches to the treatment of breast cancer, around the corner? 183
Locoregional recurrence in patients with HER2 positive breast cancer 182
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus 182
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 179
RNAi screens identify CHD4 as an essential gene in breast cancer growth 179
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials 179
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 177
WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells 176
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 176
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 170
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 168
Adjuvant treatment of early male breast cancer 168
Cardiotoxicity of anticancer treatments : epidemiology, detection, and management 166
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials 164
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 162
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 162
HER2-Low Breast Cancer: a New Subtype? 162
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 162
Characterization of low HER2 expressions in de-novo metastatic breast cancer 158
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives 158
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer 158
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 157
Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an "innocent bystander" 157
No link between breast cancer and meningioma : results from a large monoinstitutional retrospective analysis 157
Trop-2 as an Actionable Biomarker in Breast Cancer 154
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 154
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 152
Best management of locally advanced inoperable breast cancer 152
Peptide vaccines in early breast cancer 149
Breast conservation following neoadjuvant therapy for breast cancer in the modern era : are we losing the opportunity? 148
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer : a retrospective multicenter study 147
Targeting brain metastases in breast cancer 147
Targeting fibroblast growth factor receptor pathway in breast cancer 146
Cardiotoxicity of Agents Used in Patients With Breast Cancer 145
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 144
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 144
Molecular tumor board in patients with metastatic breast cancer 142
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. 141
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer 140
Molecular pathways : human leukocyte antigen G(HLA-G) 140
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 139
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 138
Successes and limitations of targeted cancer therapy in breast cancer 137
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores 137
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 135
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status 135
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 135
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 133
Totale 23.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.141
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.141
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021382 0 0 0 0 0 0 0 0 0 0 184 198
2021/20221.529 140 136 96 97 137 96 148 75 212 106 62 224
2022/20231.646 181 155 178 155 129 267 63 122 186 41 111 58
2023/20244.057 111 152 101 180 319 252 557 466 258 466 582 613
2024/20256.001 525 557 478 532 377 239 180 584 316 577 543 1.093
2025/202612.305 1.228 1.135 1.640 1.059 932 691 1.503 596 1.254 901 1.366 0
Totale 31.924